Neurocrine Biosciences (NBIX) EBT Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) EBT Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.05% |
| Mar 31, 2026 | 55.44% |
| Dec 31, 2025 | 41.84% |
| Sep 30, 2025 | 48.04% |
| Jun 30, 2025 | 13.90% |
| Mar 31, 2025 | -17.69% |
| Dec 31, 2024 | 33.32% |
| Sep 30, 2024 | 26.65% |
| Jun 30, 2024 | 13.61% |
| Mar 31, 2024 | 18.50% |
| Dec 31, 2023 | 60.23% |
| Sep 30, 2023 | 17.89% |
| Jun 30, 2023 | 86.50% |
| Mar 31, 2023 | -19.82% |
| Dec 31, 2022 | 62.83% |
| Sep 30, 2022 | 52.32% |
| Jun 30, 2022 | 19.29% |
| Mar 31, 2022 | 17.82% |
| Dec 31, 2021 | 19.47% |
| Sep 30, 2021 | 22.78% |